Date: 17 August 2015
A Direct Healthcare Professional Communication (DHPC) has been approved by NPCB to inform healthcare professionals that serious cases of diabetic ketoacidosis (DKA) have been reported in patients on SGLT2 inhibitor treatment for type 2 diabetes. A number of these cases reported patients presenting with only moderately increased blood glucose levels. Such atypical presentation of DKA could delay diagnosis and treatment. Patients on SGLT2 inhibitors who present with symptoms of acidosis should be tested for ketones, to ensure quick diagnosis and management. Please refer to the DHPC for further information.